WallStSmart

Guardant Health Inc (GH)vsWaters Corporation (WAT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Waters Corporation generates 249% more annual revenue ($3.77B vs $1.08B). WAT leads profitability with a 11.9% profit margin vs -40.1%. WAT earns a higher WallStSmart Score of 50/100 (C-).

GH

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: -1.58

WAT

Buy

50

out of 100

Grade: C-

Growth: 5.3Profit: 5.0Value: 3.3Quality: 7.0
Piotroski: 2/9Altman Z: 4.85
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for GH.

WATSignificantly Overvalued (-84.6%)

Margin of Safety

-84.6%

Fair Value

$178.29

Current Price

$365.36

$187.07 premium

UndervaluedFair: $178.29Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GH2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
48.3%10/10

Revenue surging 48.3% year-over-year

Debt/EquityHealth
-9.2610/10

Conservative balance sheet, low leverage

WAT2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
91.4%10/10

Revenue surging 91.4% year-over-year

Altman Z-ScoreHealth
4.8510/10

Safe zone — low bankruptcy risk

Areas to Watch

GH4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-4584.0%2/10

ROE of -4584.0% — below average capital efficiency

Free Cash FlowQuality
$-71.20M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
-1.582/10

Distress zone — elevated risk

WAT4 concerns · Avg: 3.5/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
2.9%3/10

ROE of 2.9% — below average capital efficiency

Operating MarginProfitability
2.8%3/10

Operating margin of 2.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : GH

The strongest argument for GH centers on Revenue Growth, Debt/Equity. Revenue growth of 48.3% demonstrates continued momentum.

Bull Case : WAT

The strongest argument for WAT centers on Revenue Growth, Altman Z-Score. Revenue growth of 91.4% demonstrates continued momentum.

Bear Case : GH

The primary concerns for GH are EPS Growth, Return on Equity, Free Cash Flow.

Bear Case : WAT

The primary concerns for WAT are PEG Ratio, Price/Book, Return on Equity. A P/E of 45.2x leaves little room for execution misses.

Key Dynamics to Monitor

GH profiles as a hypergrowth stock while WAT is a growth play — different risk/reward profiles.

GH carries more volatility with a beta of 1.62 — expect wider price swings.

WAT is growing revenue faster at 91.4% — sustainability is the question.

WAT generates stronger free cash flow (-42M), providing more financial flexibility.

Bottom Line

WAT scores higher overall (50/100 vs 31/100) and 91.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Guardant Health Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Guardant Health, Inc., a precision oncology company, offers blood testing, data sets, and testing in the United States and internationally. The company is headquartered in Redwood City, California.

Visit Website →

Waters Corporation

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.

Want to dig deeper into these stocks?